| Literature DB >> 31097996 |
Fu-Lian Hsu1, Su Y Bae1, Jack McGuire2, Dana R Anderson3, Stephanie M Bester2, Jude J Height1, Scott D Pegan1,2,3, Andrew J Walz1.
Abstract
The threat of a deliberate release of chemical nerve agents has underscored the need to continually improve field effective treatments for these types of poisonings. The oxime containing HLö-7 is a potential second-generation therapeutic reactivator. A synthetic process for HLö-7 is detailed with improvements to the DIBAL reduction and ion exchange steps. HLö-7 was visualized for the first time within the active site of human acetylcholinesterase and its relative ex vivo potency confirmed against various nerve agents using a phrenic nerve hemidiaphragm assay.Entities:
Year: 2019 PMID: 31097996 PMCID: PMC6511945 DOI: 10.1021/acsmedchemlett.9b00021
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345